News

Press Releases

Apr 26, 2022

Jnana Therapeutics Announces Appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer

BOSTON, Mass., April 26, 2022 – Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to address well-validated but hard-to-drug targets, today announced the appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer. Mr. Pagán will be responsible for spearheading the company’s finance, operations and IT functions, including capital […]

Read More >

Feb 23, 2022

Jnana Therapeutics to Advance JNT-517 as Development Candidate and Potential First-in-Class Oral Treatment for PKU

– Phase 1 clinical study expected to begin late this year – –  Cryo-EM structure reveals Jnana’s proprietary inhibitors, identified using its RAPID platform, bind the target in a cryptic allosteric site –   Boston, Mass., February 23, 2022 – Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to address well-validated but […]

Read More >

IN THE NEWS

Aug 18, 2021

Jnana closes $50M series B round, picks PKU as lead indication

BioWorld

Aug 18, 2021

Jnana nets $50M to push newly unveiled PKU program, expand into more hard-to-drug targets

Fierce Biotech

Oct 12, 2020

Fragment-based screening sees the light

Nature Reviews Drug Discovery, October 2020

Jul 22, 2020

Roche, Jnana sign multi-target collaboration deal for small molecule drugs

Pharmaceutical Business Review

Jul 21, 2020

Roche, Jnana Enter Drug R&D Alliance Targeting Metabolism’s Gatekeepers

Xconomy

Jul 21, 2020

Roche, Jnana take aim at metabolite transporters in $40M discovery deal

Fierce Biotech

Apr 16, 2020

Scripps Research expands international effort to rapidly repurpose existing drugs against COVID-19

Scripps Research, April 2020

Oct 14, 2018

Jnana Therapeutics tries to take on an untapped class of proteins

Chemical and Engineering News, October 2018

WANT TO STAY CONNECTED?

Back to Top
 

This links to an external website. Merus is not responsible for any third party content.

Continue